Terns Pharmaceuticals, Inc. Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2025-12-31..
Quick ratio
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 16.41M USD | Liabilities, Current |
| Cash and equivalents | 524.75M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 494.24M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | (m) | $16.41M | $524.75M | $494.24M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $15.39M | $150.70M | $144.94M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $12.91M | $145.97M | $169.48M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $10.94M | $139.02M | $195.24M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $15.65M | $161.44M | $196.72M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $11.41M | $270.14M | $102.64M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $10.96M | $91.50M | $133.80M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $8.83M | $65.10M | $175.56M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $11.94M | $79.93M | $183.51M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $12.09M | $37.89M | $228.71M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $14.24M | $80.92M | $204.68M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $12.11M | $184.35M | $113.17M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $8.47M | $143.24M | $139.88M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $7.48M | $62.98M | $124.31M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $6.04M | $16.81M | $123.00M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $6.17M | $43.88M | $107.39M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $6.82M | $47.70M | $118.28M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $6.89M | $64.75M | $112.44M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $5.82M | $67.59M | $117.50M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $8.38M | $98.83M | $96.75M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $22.82M | $74.85M | $0.00 | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $13.76M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $19.59M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $11.70M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.